Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 817 to 827 of 827 entries
Sorted by: Best Match Show Resources per page
Predictors of Improvement in Quality of Life When Treating Hypothyroidism.

Journal of thyroid research

Medici BB, Lerche la Cour J, Knop FK, Krakauer M, Michaelsson LF, Faber J, Watt T, Nygaard B.
PMID: 34194721
J Thyroid Res. 2021 Jun 11;2021:5577217. doi: 10.1155/2021/5577217. eCollection 2021.

BACKGROUND: Primary hypothyroidism is characterized by reduced quality of life (QoL). Although thyrotropin (TSH) is utilized as the primary indicator of thyroid disease and treatment adequacy, no simple correlation between QoL and TSH has been shown. This study aimed...

Cite
Medici BB, Lerche la Cour J, Knop FK, et al. Predictors of Improvement in Quality of Life When Treating Hypothyroidism. J Thyroid Res. 2021;2021:5577217doi: 10.1155/2021/5577217.
Medici, B. B., Lerche la Cour, J., Knop, F. K., Krakauer, M., Michaelsson, L. F., Faber, J., Watt, T., & Nygaard, B. (2021). Predictors of Improvement in Quality of Life When Treating Hypothyroidism. Journal of thyroid research, 20215577217. https://doi.org/10.1155/2021/5577217
Medici, Bjarke Borregaard, et al. "Predictors of Improvement in Quality of Life When Treating Hypothyroidism." Journal of thyroid research vol. 2021 (2021): 5577217. doi: https://doi.org/10.1155/2021/5577217
Medici BB, Lerche la Cour J, Knop FK, Krakauer M, Michaelsson LF, Faber J, Watt T, Nygaard B. Predictors of Improvement in Quality of Life When Treating Hypothyroidism. J Thyroid Res. 2021 Jun 11;2021:5577217. doi: 10.1155/2021/5577217. eCollection 2021. PMID: 34194721; PMCID: PMC8214493.
Copy Download .nbib Format: NLM
Maternal Thyroid Anomalies and Attention-Deficit Hyperactivity Disorders in Progeny.

American journal of epidemiology

Rotem RS, Chodick G, Davidovitch M, Bellavia A, Weisskopf MG.
PMID: 34791037
Am J Epidemiol. 2021 Nov 13; doi: 10.1093/aje/kwab272. Epub 2021 Nov 13.

Previous epidemiological investigations suggested that maternal thyroid anomalies are a possible causal factor in attention-deficit hyperactivity disorder (ADHD) in progeny, yet clinical trials indicated levothyroxine treatment was ineffective in preventing neurodevelopmental impairments. We used an Israeli cohort of 385,542...

Cite
Rotem RS, Chodick G, Davidovitch M, et al. Maternal Thyroid Anomalies and Attention-Deficit Hyperactivity Disorders in Progeny. Am J Epidemiol. 2021;doi: 10.1093/aje/kwab272.
Rotem, R. S., Chodick, G., Davidovitch, M., Bellavia, A., & Weisskopf, M. G. (2021). Maternal Thyroid Anomalies and Attention-Deficit Hyperactivity Disorders in Progeny. American journal of epidemiology, . https://doi.org/10.1093/aje/kwab272
Rotem, Ran S, et al. "Maternal Thyroid Anomalies and Attention-Deficit Hyperactivity Disorders in Progeny." American journal of epidemiology vol. (2021). doi: https://doi.org/10.1093/aje/kwab272
Rotem RS, Chodick G, Davidovitch M, Bellavia A, Weisskopf MG. Maternal Thyroid Anomalies and Attention-Deficit Hyperactivity Disorders in Progeny. Am J Epidemiol. 2021 Nov 13; doi: 10.1093/aje/kwab272. Epub 2021 Nov 13. PMID: 34791037.
Copy Download .nbib Format: NLM
123I Scintigraphy Mirror Image of Graves Disease Induced by Radioiodine Treatment for Toxic Adenoma.

Clinical nuclear medicine

Lugat A, Drui D, Bach-Ngohou K, Guillot P, Mourrain-Langlois E, Kraeber-Bodéré F, Ansquer C.
PMID: 35006119
Clin Nucl Med. 2022 Feb 01;47(2):e197-e198. doi: 10.1097/RLU.0000000000003884.

ABSTRACT: A 61-year-old woman presenting with hyperthyroidism received 131I therapy for a toxic adenoma diagnosed by 123I scintigraphy. Six months later, the patient had a relapse of hyperthyroidism, and 123I scintigraphy showed a mirror image of the first scintigraphy:...

Cite
Lugat A, Drui D, Bach-Ngohou K, et al. 123I Scintigraphy Mirror Image of Graves Disease Induced by Radioiodine Treatment for Toxic Adenoma. Clin Nucl Med. 2022;47(2):e197-e198doi: 10.1097/RLU.0000000000003884.
Lugat, A., Drui, D., Bach-Ngohou, K., Guillot, P., Mourrain-Langlois, E., Kraeber-Bodéré, F., & Ansquer, C. (2022). 123I Scintigraphy Mirror Image of Graves Disease Induced by Radioiodine Treatment for Toxic Adenoma. Clinical nuclear medicine, 47(2), e197-e198. https://doi.org/10.1097/RLU.0000000000003884
Lugat, Alexandre, et al. "123I Scintigraphy Mirror Image of Graves Disease Induced by Radioiodine Treatment for Toxic Adenoma." Clinical nuclear medicine vol. 47,2 (2022): e197-e198. doi: https://doi.org/10.1097/RLU.0000000000003884
Lugat A, Drui D, Bach-Ngohou K, Guillot P, Mourrain-Langlois E, Kraeber-Bodéré F, Ansquer C. 123I Scintigraphy Mirror Image of Graves Disease Induced by Radioiodine Treatment for Toxic Adenoma. Clin Nucl Med. 2022 Feb 01;47(2):e197-e198. doi: 10.1097/RLU.0000000000003884. PMID: 35006119.
Copy Download .nbib Format: NLM
Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.

Journal of endocrinological investigation

Sarić Matutinović M, Diana T, Nedeljković Beleslin B, Ćirić J, Žarković M, Kahaly GJ, Ignjatović S.
PMID: 34324163
J Endocrinol Invest. 2021 Jul 29; doi: 10.1007/s40618-021-01652-y. Epub 2021 Jul 29.

PURPOSE: Thyrotropin receptor autoantibodies (TSH-R-Ab) are heterogeneous in their biological function and play a significant role in the pathophysiology of both Graves' disease and Graves' orbitopathy (GO). The clinical significance and utility of determining functional TSH-R-Ab in a Serbian...

Cite
Sarić Matutinović M, Diana T, Nedeljković Beleslin B, et al. Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy. J Endocrinol Invest. 2021;doi: 10.1007/s40618-021-01652-y.
Sarić Matutinović, M., Diana, T., Nedeljković Beleslin, B., Ćirić, J., Žarković, M., Kahaly, G. J., & Ignjatović, S. (2021). Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy. Journal of endocrinological investigation, . https://doi.org/10.1007/s40618-021-01652-y
Sarić Matutinović, M, et al. "Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy." Journal of endocrinological investigation vol. (2021). doi: https://doi.org/10.1007/s40618-021-01652-y
Sarić Matutinović M, Diana T, Nedeljković Beleslin B, Ćirić J, Žarković M, Kahaly GJ, Ignjatović S. Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy. J Endocrinol Invest. 2021 Jul 29; doi: 10.1007/s40618-021-01652-y. Epub 2021 Jul 29. PMID: 34324163.
Copy Download .nbib Format: NLM
Calcium/calmodulin-dependent kinases can regulate the TSH expression in the rat pituitary.

Journal of endocrinological investigation

Altobelli GG, Van Noorden S, Cimini D, Illario M, Sorriento D, Cimini V.
PMID: 33743173
J Endocrinol Invest. 2021 Nov;44(11):2387-2394. doi: 10.1007/s40618-021-01545-0. Epub 2021 Mar 20.

PURPOSE: The endocrine secretion of TSH is a finely orchestrated process controlled by the thyrotropin-releasing hormone (TRH). Its homeostasis and signaling rely on many calcium-binding proteins belonging to the "EF-hand" protein family. The CaMETHODS: The expression of CaMKII and...

Cite
Altobelli GG, Van Noorden S, Cimini D, et al. Calcium/calmodulin-dependent kinases can regulate the TSH expression in the rat pituitary. J Endocrinol Invest. 2021;44(11):2387-2394doi: 10.1007/s40618-021-01545-0.
Altobelli, G. G., Van Noorden, S., Cimini, D., Illario, M., Sorriento, D., & Cimini, V. (2021). Calcium/calmodulin-dependent kinases can regulate the TSH expression in the rat pituitary. Journal of endocrinological investigation, 44(11), 2387-2394. https://doi.org/10.1007/s40618-021-01545-0
Altobelli, G G, et al. "Calcium/calmodulin-dependent kinases can regulate the TSH expression in the rat pituitary." Journal of endocrinological investigation vol. 44,11 (2021): 2387-2394. doi: https://doi.org/10.1007/s40618-021-01545-0
Altobelli GG, Van Noorden S, Cimini D, Illario M, Sorriento D, Cimini V. Calcium/calmodulin-dependent kinases can regulate the TSH expression in the rat pituitary. J Endocrinol Invest. 2021 Nov;44(11):2387-2394. doi: 10.1007/s40618-021-01545-0. Epub 2021 Mar 20. PMID: 33743173.
Copy Download .nbib Format: NLM
Influence of 4-week or 12-week glucocorticoid treatment on metabolic changes in patients with active moderate-to-severe thyroid-associated ophthalmopathy.

Clinical and translational science

Chen X, Abudukerimu B, Li Q, Li Q, Qiao J, Lin D, Sui C, Ye L, Zhai H, Jiang B, Wang N, Jiang M, Tao X, Shao Z, Zhu C, Ma Y, Xiong P, Sun J, Zhou H, Han B, Lu Y.
PMID: 33742766
Clin Transl Sci. 2021 Sep;14(5):1734-1746. doi: 10.1111/cts.12999. Epub 2021 May 03.

Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening and difficult-to-treat organ-specific autoimmune disease. The course, therapeutic effects and prognosis of moderate to severe TAO vary greatly. High-dose intravenous glucocorticoid (IVGC) therapy is considered a first-line treatment for active moderate-to-severe...

Cite
Chen X, Abudukerimu B, Li Q, et al. Influence of 4-week or 12-week glucocorticoid treatment on metabolic changes in patients with active moderate-to-severe thyroid-associated ophthalmopathy. Clin Transl Sci. 2021;14(5):1734-1746doi: 10.1111/cts.12999.
Chen, X., Abudukerimu, B., Li, Q., Li, Q., Qiao, J., Lin, D., Sui, C., Ye, L., Zhai, H., Jiang, B., Wang, N., Jiang, M., Tao, X., Shao, Z., Zhu, C., Ma, Y., Xiong, P., Sun, J., Zhou, H., Han, B., & Lu, Y. (2021). Influence of 4-week or 12-week glucocorticoid treatment on metabolic changes in patients with active moderate-to-severe thyroid-associated ophthalmopathy. Clinical and translational science, 14(5), 1734-1746. https://doi.org/10.1111/cts.12999
Chen, Xiaoman, et al. "Influence of 4-week or 12-week glucocorticoid treatment on metabolic changes in patients with active moderate-to-severe thyroid-associated ophthalmopathy." Clinical and translational science vol. 14,5 (2021): 1734-1746. doi: https://doi.org/10.1111/cts.12999
Chen X, Abudukerimu B, Li Q, Li Q, Qiao J, Lin D, Sui C, Ye L, Zhai H, Jiang B, Wang N, Jiang M, Tao X, Shao Z, Zhu C, Ma Y, Xiong P, Sun J, Zhou H, Han B, Lu Y. Influence of 4-week or 12-week glucocorticoid treatment on metabolic changes in patients with active moderate-to-severe thyroid-associated ophthalmopathy. Clin Transl Sci. 2021 Sep;14(5):1734-1746. doi: 10.1111/cts.12999. Epub 2021 May 03. PMID: 33742766; PMCID: PMC8504830.
Copy Download .nbib Format: NLM
Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

Altuntaş SÇ, Hocaoğlu Ç.
PMID: 34607367
Horm Metab Res. 2021 Oct;53(10):683-691. doi: 10.1055/a-1639-1024. Epub 2021 Oct 04.

In differentiated thyroid cancer (DTC), the standard treatment includes total thyroidectomy and lifetime levothyroxine (LT4) replacement. However, long-term exogenous LT4 has become controversial due to the adverse effects of oversuppression. The study included 191 patients (aged 18-76 years) with...

Cite
Altuntaş SÇ, Hocaoğlu Ç. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer. Horm Metab Res. 2021;53(10):683-691doi: 10.1055/a-1639-1024.
Altuntaş, S. �. �., & Hocaoğlu, �. �. (2021). Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 53(10), 683-691. https://doi.org/10.1055/a-1639-1024
Altuntaş, Seher Çetinkaya, and Hocaoğlu, Çiçek. "Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer." Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme vol. 53,10 (2021): 683-691. doi: https://doi.org/10.1055/a-1639-1024
Altuntaş SÇ, Hocaoğlu Ç. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer. Horm Metab Res. 2021 Oct;53(10):683-691. doi: 10.1055/a-1639-1024. Epub 2021 Oct 04. PMID: 34607367.
Copy Download .nbib Format: NLM
Triiodothyronine alongside levothyroxine in the management of hypothyroidism?.

Current medical research and opinion

Gottwald-Hostalek U, Kahaly GJ.
PMID: 34553643
Curr Med Res Opin. 2021 Dec;37(12):2099-2106. doi: 10.1080/03007995.2021.1984219. Epub 2021 Oct 12.

The current guideline-based management of hypothyroidism recommends monotherapy with levothyroxine (LT4), titrated to maintain the level of thyrotropin within a euthyroid reference range. This has been successful for most people with hypothyroidism, but a substantial minority still report symptoms...

Cite
Gottwald-Hostalek U, Kahaly GJ. Triiodothyronine alongside levothyroxine in the management of hypothyroidism?. Curr Med Res Opin. 2021;37(12):2099-2106doi: 10.1080/03007995.2021.1984219.
Gottwald-Hostalek, U., & Kahaly, G. J. (2021). Triiodothyronine alongside levothyroxine in the management of hypothyroidism?. Current medical research and opinion, 37(12), 2099-2106. https://doi.org/10.1080/03007995.2021.1984219
Gottwald-Hostalek, Ulrike, and Kahaly, George J. "Triiodothyronine alongside levothyroxine in the management of hypothyroidism?." Current medical research and opinion vol. 37,12 (2021): 2099-2106. doi: https://doi.org/10.1080/03007995.2021.1984219
Gottwald-Hostalek U, Kahaly GJ. Triiodothyronine alongside levothyroxine in the management of hypothyroidism?. Curr Med Res Opin. 2021 Dec;37(12):2099-2106. doi: 10.1080/03007995.2021.1984219. Epub 2021 Oct 12. PMID: 34553643.
Copy Download .nbib Format: NLM
Correction to: Thyrotropin receptor antibodies and Graves' orbitopathy.

Journal of endocrinological investigation

Diana T, Ponto KA, Kahaly GJ.
PMID: 34302685
J Endocrinol Invest. 2021 Jul 24; doi: 10.1007/s40618-021-01632-2. Epub 2021 Jul 24.

No abstract available.

Cite
Diana T, Ponto KA, Kahaly GJ. Correction to: Thyrotropin receptor antibodies and Graves' orbitopathy. J Endocrinol Invest. 2021;doi: 10.1007/s40618-021-01632-2.
Diana, T., Ponto, K. A., & Kahaly, G. J. (2021). Correction to: Thyrotropin receptor antibodies and Graves' orbitopathy. Journal of endocrinological investigation, . https://doi.org/10.1007/s40618-021-01632-2
Diana, T, et al. "Correction to: Thyrotropin receptor antibodies and Graves' orbitopathy." Journal of endocrinological investigation vol. (2021). doi: https://doi.org/10.1007/s40618-021-01632-2
Diana T, Ponto KA, Kahaly GJ. Correction to: Thyrotropin receptor antibodies and Graves' orbitopathy. J Endocrinol Invest. 2021 Jul 24; doi: 10.1007/s40618-021-01632-2. Epub 2021 Jul 24. PMID: 34302685.
Copy Download .nbib Format: NLM
The impact of levothyroxine on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity in men with autoimmune hypothyroidism and early-onset androgenetic alopecia.

Endokrynologia Polska

Krysiak R, Kowalcze K, Marek B, Okopień B.
PMID: 34378784
Endokrynol Pol. 2021;72(5):498-504. doi: 10.5603/EP.a2021.0071. Epub 2021 Aug 11.

INTRODUCTION: Administration of testosterone or dehydroepiandrosterone to subjects with low levels of these hormones was found to reduce thyroid antibody titres. Male-pattern baldness is accompanied by mildly increased androgen levels. The present study was aimed at investigating whether early-onset...

Cite
Krysiak R, Kowalcze K, Marek B, et al. The impact of levothyroxine on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity in men with autoimmune hypothyroidism and early-onset androgenetic alopecia. Endokrynol Pol. 2021;72(5):498-504doi: 10.5603/EP.a2021.0071.
Krysiak, R., Kowalcze, K., Marek, B., & Okopień, B. (2021). The impact of levothyroxine on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity in men with autoimmune hypothyroidism and early-onset androgenetic alopecia. Endokrynologia Polska, 72(5), 498-504. https://doi.org/10.5603/EP.a2021.0071
Krysiak, Robert, et al. "The impact of levothyroxine on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity in men with autoimmune hypothyroidism and early-onset androgenetic alopecia." Endokrynologia Polska vol. 72,5 (2021): 498-504. doi: https://doi.org/10.5603/EP.a2021.0071
Krysiak R, Kowalcze K, Marek B, Okopień B. The impact of levothyroxine on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity in men with autoimmune hypothyroidism and early-onset androgenetic alopecia. Endokrynol Pol. 2021;72(5):498-504. doi: 10.5603/EP.a2021.0071. Epub 2021 Aug 11. PMID: 34378784.
Copy Download .nbib Format: NLM
Clinical and Therapeutic Characteristics of Pituitary TSH-Secreting Adenoma in Adolescent-Onset Patients: Six Case Studies and Literature Review.

Frontiers in endocrinology

Yang Y, Liu J, Deng K, Lu L, Zhu H, Lian X, Bao X, Duan L, Yao Y.
PMID: 35002961
Front Endocrinol (Lausanne). 2021 Dec 23;12:771673. doi: 10.3389/fendo.2021.771673. eCollection 2021.

BACKGROUND: Thyrotropin-secreting adenoma (TSH-oma) is a very rare kind of functional pituitary adenoma, especially that which occurs in adolescents. However, its potential clinical and therapeutic characteristics are still unknown.OBJECTIVES: The study was aimed to summarize the clinical and therapeutic...

Cite
Yang Y, Liu J, Deng K, et al. Clinical and Therapeutic Characteristics of Pituitary TSH-Secreting Adenoma in Adolescent-Onset Patients: Six Case Studies and Literature Review. Front Endocrinol (Lausanne). 2021;12:771673doi: 10.3389/fendo.2021.771673.
Yang, Y., Liu, J., Deng, K., Lu, L., Zhu, H., Lian, X., Bao, X., Duan, L., & Yao, Y. (2021). Clinical and Therapeutic Characteristics of Pituitary TSH-Secreting Adenoma in Adolescent-Onset Patients: Six Case Studies and Literature Review. Frontiers in endocrinology, 12771673. https://doi.org/10.3389/fendo.2021.771673
Yang, Yamei, et al. "Clinical and Therapeutic Characteristics of Pituitary TSH-Secreting Adenoma in Adolescent-Onset Patients: Six Case Studies and Literature Review." Frontiers in endocrinology vol. 12 (2021): 771673. doi: https://doi.org/10.3389/fendo.2021.771673
Yang Y, Liu J, Deng K, Lu L, Zhu H, Lian X, Bao X, Duan L, Yao Y. Clinical and Therapeutic Characteristics of Pituitary TSH-Secreting Adenoma in Adolescent-Onset Patients: Six Case Studies and Literature Review. Front Endocrinol (Lausanne). 2021 Dec 23;12:771673. doi: 10.3389/fendo.2021.771673. eCollection 2021. PMID: 35002961; PMCID: PMC8734954.
Copy Download .nbib Format: NLM
Showing 817 to 827 of 827 entries